Editorial on the Research Topic
Lipids, Lipoproteins and COVID-19
Introduction
Coronavirus disease-19 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus
2 (SARS-CoV-2), not only impacts the respiratory system but often exhibits extrapulmonary
involvement, resulting in systemic disease (1). Existing studies suggest a complex
interplay between the virus and various organ systems, including cardiovascular, cerebrovascular,
gastrointestinal, musculoskeletal, endocrine, and renal systems.
While the mechanisms driving these pulmonary and extrapulmonary manifestations of
COVID-19 remain under investigation, dysregulated immune responses and coagulation
abnormalities characterized by hypercoagulation and microthrombosis, may play significant
roles. Additionally, numerous studies have pointed to a potential connection between
lipid levels and disease severity, suggesting a prognostic and/or therapeutic utility
of lipids and lipoproteins in COVID-19.
Cardiovascular disease and COVID-19
COVID-19 and cardiovascular disease have a bidirectional relationship. On one hand,
preexisting cardiovascular risk factors such as hypertension and diabetes, along with
chronic cardiovascular conditions, predispose to severe disease. Conversely, COVID-19
can lead to cardiovascular complications, including acute heart failure, arrhythmias,
venous thromboembolism, cardiogenic shock, arterial thrombosis, myocardial ischemia
or infarction, and myocarditis (2, 3). Moreover, COVID-19 can increase biomarkers
of myocardial injury (3–5), but often in the absence of overt cardiac symptoms. The
cardiovascular system involvement in COVID-19 has important consequences during recovery
from infection and the development of long COVID (1).
Despite the evidence of acute cardiac manifestations of COVID-19, a study by Matejova
et al. revealed that in patients with a history of hospitalization due to COVID-19,
one-year follow-up echocardiography indicated only a subtle left ventricle diastolic
impairment and left atrial enlargement, which was not clinically significant. On the
other hand, Bürgi et al. observed a significant increase in high-sensitivity troponin
I levels among men aged 54 or older after infection, and these elevated levels persisted
for at least 14 months, suggesting a potential ongoing myocardial injury, albeit without
clear clinical significance. These findings shed valuable light on the need for future
long-term studies to investigate cardiovascular outcomes of COVID-19.
Cerebrovascular disease and COVID-19
Stroke and other cerebrovascular events appear to be uncommon complications of COVID-19,
but when they occur, they can significantly increase morbidity and mortality. Moreover,
a study by De Michele et al. demonstrated that COVID-19 extends the infarct volume
during acute ischemic stroke (AIS), one of the feared complications of COVID-19. Though
the mechanisms underlying AIS are not yet fully known, it is thought to be driven
by multiple pathophysiological factors, including hypercoagulation and microthrombosis.
De Michele et al. demonstrated that COVID-19 increases biomarkers of endothelial dysfunction
and hence plays a major role in endothelial activation, which can potentially explain
the increased risk and severity of AIS in COVID-19.
Lipids and COVID-19
Studies have consistently observed alterations in lipid profiles in patients with
COVID-19. Total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density
lipoprotein cholesterol (HDL-C), cholesterol metabolite 27-hydroxycholesterol, and
apolipoprotein M, B and A-I levels often decrease in patients with COVID-19, similar
to trends seen in other infections (6–8). Chidambaram et al. demonstrated that the
decreases in total cholesterol and HDL-C, measured at the time of admission, were
more pronounced in patients with severe disease and those who did not survive. Hence,
they suggested that lipids may serve as biomarkers for predicting disease severity
and mortality. In addition to HDL-C, Mietus-Snyder et al. highlighted the significance
of other lipid particles, including total, large, and small HDL particles, as well
as HDL functional cholesterol efflux capacity (CEC), in relation to the severity of
COVID-19 among pediatric patients. Consequently, they have suggested a potential prognostic
role of HDL parameters in COVID-19, particularly among youth.
Mechanistically, cholesterol in the host cell plasma membrane influences the entry
of SARS-CoV-2. Serum lipids, particularly LDL-C and HDL-C, are in constant interaction
with the lipid rafts in the host cell membranes and can modulate virus-host cell interactions
and disease severity (Chidambaram et al., 9, 10). Adipose tissue has also been implicated
in contributing to the hyper-inflammatory state seen in severe COVID-19 cases and
being responsible for their poor prognoses, including death (11, 12).
Apolipoproteins have emerged as predictive biomarkers for various diseases, including
COVID-19 (8, 13). Supporting this, Mietus-Snyder et al. demonstrated that a decrease
in apolipoprotein A-I is associated with increased clinical severity in COVID-19.
Additionally, both preclinical and clinical studies indicated a potential therapeutic
role of apolipoproteins and agents targeting them in various disease settings, including
COVID-19 (13–16). Apolipoproteins influence human vascular biology and atherosclerotic
cardiovascular disease (17). Hence, one of the potential mechanistic hallmarks underlying
the benefits of apolipoproteins is suggested to be protection against COVID-19-induced
endothelial dysfunction.
Lipid-lowering therapy and COVID-19
In patients with COVID-19, the most severe complication is sepsis. While LDL-C is
a well-known risk factor for coronary heart disease, it is noteworthy that both LDL-C
and HDL-C play protective roles against infection and sepsis. A study conducted by
Felici et al. revealed significant reductions in LDL-C and HDL-C in patients with
sepsis and these derangements persisted in long-term after recovery from sepsis. Interestingly,
Gong et al. showed that both low and high LDL-C levels are associated with an increased
risk of severe COVID-19. Consequently, lipid-lowering therapy should be performed
cautiously as plasma LDL-C levels could potentially have a dual impact on these patients,
similar to a double-edged sword.
Statins, known as 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA) inhibitors,
are well-known lipid-lowering drugs, decreasing LDL-C levels. Beyond their cholesterol-lowering
effects, they have also been suggested to have a wide range of pleiotropic effects,
including anti-inflammatory, antithrombotic, and antioxidant effects. Kouhpeikar et
al. demonstrated that statins decreased the composite outcomes of mortality, ICU admissions,
and intubations among COVID-19 patients. Statin treatment also lowered inflammatory
markers, including C-reactive protein (CRP) levels and neutrophil counts. These findings
suggest a potential anti-inflammatory role of statins in mitigating the composite
adverse outcomes associated with COVID-19.
Conclusion
In conclusion, the articles published in this research topic hold immense importance
in understanding the pathophysiology, diagnosis, prognosis, and treatment of COVID-19
(Matejova et al., Bürgi et al., De Michele et al., Chidambaram et al., Mietus-Snyder
et al., Felici et al., Gong et al., Kouhpeikar et al.). Further research is necessary
to establish a theoretical and clinical foundation for using lipids as biomarkers
for both COVID-19 and sepsis prognosis. Additionally, the potential role of lipid-lowering
therapies and apolipoproteins in COVID-19 treatment warrants further thorough investigation.